Entries by TDC

The Jenex Corporation, in Collaboration with UHN’s Techna Institute, Reports Promising Initial Results on Zika Virus Testing with TherOZap(TM)

Toronto, Ontario–(Newsfile Corp. – October 12, 2017) - The Jenex Corporation (TSXV: JEN.H) (“Jenex” or the “Company”), a progressive medical device technology company, today announces that it has received promising initial results on the Zika virus testing with TherOZap™. Dr. Alyson Kelvin at UHN reported the following: “To evaluate the effectiveness of the Jenex TherOZap™ device against the infectivity of […]

UHN Start-up AVROBIO, Inc. Expands Rare Disease Pipeline with Gene Therapy to Treat Cystinosis

Cystinosis Program Becomes Company’s Fourth Gene Therapy  for Lysosomal Storage Disorders Cambridge, MA, October 4, 2017 – AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapies for rare diseases, today announced the expansion of its pipeline to cystinosis. This program becomes AVROBIO’s fourth gene therapy for lysosomal storage disorders (LSDs), and with an anticipated IND […]

Bauer Launches Innovative NeuroShield in Canada, Co-Invented by the Founder of UHN Spin-off Thornhill Medical

PRESS RELEASE  UPDATED: SEP 26, 2017 08:00 EDT TORONTO, September 26, 2017 (Newswire.com)  Bauer, the world’s leading manufacturer of ice hockey equipment, recently launched the first athletic product clinically shown to help protect the brain from the inside during sports-related impacts. Continuing Bauer Hockey’s rich history of delivering game-changing technologies, the BAUER NeuroShield collar revolutionizes head protection with […]

UHN Start-up AVROBIO, Inc. Expands Rare Disease Pipeline with Gene Therapy to Treat Pompe Disease

Pre-Clinical Program Becomes Company’s Third GeneTherapy for Lysosomal Storage Disorders Pre-Clinical Proof-of-Concept Demonstrated Cambridge, MA, September 20, 2017 – AVROBIO, Inc., a clinical-stage biotechnology company developing transformative, life-changing gene therapies for rare diseases, today announced the expansion of its pipeline to Pompe disease. This pre-clinical program becomes AVROBIO’s third gene therapy for Lysosomal Storage Disorders (LSDs), following […]

UHN Start-up MyndTec Announces 510(k) Clearance for MyndMove® Therapy for Individuals with Upper Extremity Paralysis

MISSISSAUGA, ON, Sept. 8, 2017 /CNW/ – MyndTec, an award-winning Canadian medical technology company announced today it has received 510(k) clearance to market its landmark product MyndMove®.  MyndTec is a pioneer in the treatment of arm and hand paralysis caused by stroke or spinal cord injury. “This is a major milestone in the evolution of our company,” said […]

UHN’s Techna Institute, in Collaboration with Jenex, to release initial results on Zika virus deactivation testing

For Immediate Release NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES Jenex Reports Expected Date of Test Results for TherOZap™ at Inactivating the Zika Virus Toronto, Ontario – (September 14, 2017) The Jenex Corporation (“Jenex”, or the “Company”, NEX: JEN.H), a progressive medical device technology company, would like to report that the Techna Institute […]

We’re hiring: Commercialization Intern (8 months full-time, Oct-May)

Are you a graduated student with an interest in commercialization? Experience with market analysis? A scientific background? Join the TDC team as our TDC Commercialization Intern starting this Fall, 2017. Please note this opportunity is not available to current students. Job Title:  Commercialization Intern (8 months full-time, Oct-May) Company Name:  University Health Network, Office of Technology […]

Tribute to Dr. Michael Sharpe, UHN Researcher, for Contribution to the Advancement of Radiation Therapy

TDC is proud to have helped enable an important advance in radiation therapy and radiation therapy training, and to honor the memory of one of our great inventors, Dr. Michael Sharpe. In this video, UHN outlines the impact of the automatic treatment planning innovations it recently licensed to RaySearch, enabling algorithms from Princess Margaret Cancer […]

UHN Start-up VistaGen Receives Notice of Allowance from U.S. Patent and Trademark Office for U.S. Patent regarding Breakthrough Methods for Producing Blood Cells, Platelets and Bone Marrow Stem Cells with Potential to Treat Autoimmune Disorders and Cancer

AUGUST 08, 2017 SOUTH SAN FRANCISCO, CA — (Marketwired) — 08/08/17 – VistaGen Therapeutics Inc. (NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that the Company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for U.S. […]

BlueRock Therapeutics, Start-up based on UHN Technology, Expands Toronto Presence with R&D and Manufacturing Hub, Appoints Key R&D Leadership

Formalizes collaborations with McEwen Center for Regenerative Medicine at University Health Network, Centre for Commercialization of Regenerative Medicine Appoints Michael Scott, Ph.D., as Senior Vice President of Product Development and Toronto Operations TORONTO, Ontario and CAMBRIDGE, Mass., August 17, 2017 — BlueRock Therapeutics, which is developing cell-based therapies designed to alter the course of degenerative […]